MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells

Abstract

Background MicroRNAs (miRs) are involved in lymphoma progression by regulating tumor cell interaction with microenvironment. MiR155 is overexpressed in diffuse large B-cell lymphoma (DLBCL) and its biological effect on tumor microenvironment needs to be futher investigated. Methods MiR155 was detected by quantitative real-time PCR in patients with newly diagnosed DLBCL. The mechanism of action of miR155 on lymphoma progression and tumor microenvironment was examined in vitro in B-lymphoma cell lines and in vivo in a murine xenograft model. Results Serum miR155 was significantly elevated, correlated with tumor miR155 expression, and indicated poor disease outcome in DLBCL. MiR155 overexpression was associated with decreased peripheral blood CD8+T cells and inhibition of T-cell receptor signaling. Of note, EBV-positive patients showed higher serum miR155 than EBV-negative patients. In co-culture systems of B-lymphoma cells with immune cells, miR155 induced Fas-mediated apoptosis of CD8+T cells, which could be targeted by anti-PD-1 and anti-PD-L1 antibodies. Moreover, miR155 enhanced lymphoma cell PD-L1 expression, recruited CD8+T cells by PD-1/PD-L1 interaction and inhibited CD8+T cell function via dephosphorylating AKT and ERK. MiR155-induced AKT/ERK inactivation was more obvious in CD8+T cells co-cultured with EBV-infected B-lymphoma cells. In vivo in a murine xenograft model established with subcutaneous injection of A20 cells, PD-L1 blockade particularly retarded miR155-overexpressing tumor growth, consistent with maintenance of CD8+T cells and their function. Conclusions As a oncogenic biomarker of B-cell lymphoma, serum miR155 was related to lymphoma progression through modulating PD-1/PD-L1-mediated interaction with CD8+T cells of tumor microenvironment, indicating the sensitivity of B-cell lymphoma to PD-L1 blockade. Also CD8+T cells could be a therapeutic mediator of immune checkpoint inhibitors in treating EBV-associated lymphoid malignancies. Electronic supplementary material The online version of this article (10.1186/s12943-019-0977-3) contains supplementary material, which is available to authorized users.

An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle‐invasive bladder cancer (MIBC)

“…Therefore, it is not surprising that mir142 was highly expressed in highly infiltrating TMEs . Moreover, miR‐223, mir155, mir187, and mir200b have also been reported to be associated with the immune response, so it will be worthwhile to conduct more research exploring the relationships between noncoding RNAs and the immune response in the future.…”

The role of cancer-derived microRNAs in cancer immune escape

“…Moreover, Zheng et al observed that miR-155 induced the apoptosis of T cells by Fas-FasL pathway and upregulated the expression of PD-L1 on lymphoma cells. The results of in vivo study showed that the miR-155 overexpressed lymphoma cells were highly sensitive to PD-L1 blockade treatment [149]. More and more evidence suggested that some specific miRNA expression patterns could predict immunotherapy resistance.…”

MicroRNA‐155‐5p suppresses PD‐L1 expression in lung adenocarcinoma

“…In human dermal lymphatic endothelial cells, miR‐155‐5p was able to affect the kinetics of PD‐L1 and reduce its expression upon interferon (IFN)‐γ and tumor necrosis factor‐α treatment via directly binding to the 3′‐UTR of PD‐L1 [11]. However, in lymphoma cells, miR‐155‐5p could positively regulate the transcriptional activity of PD‐L1 and inhibit CD8 + T cell function via the PD1/PD‐L1 pathway to enhance the immune tolerance of tumor cells [12]. The contradictory findings of such studies may be the result of different experimental subjects and conditions, suggesting that the regulation of PD‐L1 by miR‐155‐5p is different in different diseases or under different conditions.…”